(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
Live Chart Being Loaded With Signals
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer...
Stats | |
---|---|
Šios dienos apimtis | 100.00 |
Vidutinė apimtis | 25.00 |
Rinkos kapitalizacija | 64.80M |
EPS | $0 ( 2024-04-22 ) |
Last Dividend | $0.500 ( 2023-10-05 ) |
Next Dividend | $0 ( N/A ) |
P/E | 11.80 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2011-10-14 | Williams Frank E Jr | Sell | 0 | Bioqual |
INSIDER POWER |
---|
0.00 |
Last 1 transactions |
Buy: 0 | Sell: 0 |
Bioqual, Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Bioqual, Inc. Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $62.66M |
Bruto pelnas: | $8.64M (13.80 %) |
EPS: | $0.930 |
FY | 2022 |
Pajamos: | $62.66M |
Bruto pelnas: | $8.64M (13.80 %) |
EPS: | $0.930 |
FY | 2018 |
Pajamos: | $35.88M |
Bruto pelnas: | $8.73M (24.31 %) |
EPS: | $4.10 |
FY | 2017 |
Pajamos: | $36.60M |
Bruto pelnas: | $9.90M (27.06 %) |
EPS: | $4.44 |
Financial Reports:
No articles found.
Bioqual, Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$1.000 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0.500 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0700 | 2004-09-02 |
Last Dividend | $0.500 | 2023-10-05 |
Next Dividend | $0 | N/A |
Payout Date | 2023-10-27 | |
Next Payout Date | N/A | |
# dividends | 19 | -- |
Total Paid Out | $7.96 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.75 | -- |
Div. Sustainability Score | 9.38 | |
Div.Growth Potential Score | 4.38 | |
Div. Directional Score | 6.88 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
MTUAY | Ex Dividend Junior | 2023-05-12 | Annually | 0 | 0.00% | |
CNLHO | Ex Dividend Knight | 2023-07-07 | Quarterly | 0 | 0.00% | |
SYIEY | Ex Dividend Knight | 2023-05-11 | Annually | 0 | 0.00% | |
HKUOF | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
ANIOY | Ex Dividend Junior | 2023-07-13 | Annually | 0 | 0.00% | |
OSAGY | No Dividend Player | 2023-06-16 | Annually | 0 | 0.00% | |
DAIUF | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
TXHPF | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
JARLF | Ex Dividend Knight | 2023-08-17 | Semi-Annually | 0 | 0.00% | |
BDVSY | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0152 | 1.500 | 9.70 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0163 | 1.200 | 9.46 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0249 | 1.500 | -0.834 | -1.251 | [0.1 - 1] |
payoutRatioTTM | 0.467 | -1.000 | 5.33 | -5.33 | [0 - 1] |
currentRatioTTM | 4.22 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.02 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.573 | 1.500 | 2.37 | 3.55 | [0.2 - 2] |
debtRatioTTM | 0.0600 | -1.500 | 9.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 10.20 | 2.00 | 6.60 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 8.87 | 2.00 | 5.57 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0910 | -1.500 | 9.64 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.141 | 1.000 | -0.978 | -0.978 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0145 | 1.000 | -1.711 | -1.711 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 2.58 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 1.068 | 0.800 | 6.21 | 4.97 | [0.5 - 2] |
Total Score | 9.38 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 67.76 | 1.000 | 3.26 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0249 | 2.50 | -0.536 | -1.251 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 8.87 | 2.00 | 7.04 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.690 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 10.20 | 2.00 | 6.60 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.467 | 1.500 | 5.33 | -5.33 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.145 | 1.000 | 8.87 | 0 | [0.1 - 0.5] |
Total Score | 4.38 |
Bioqual, Inc.
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is headquartered in Rockville, Maryland.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.